CN Patent

CN117897379A — 用于合成萘啶衍生物及其中间体的方法

Assigned to Amgen Inc · Expires 2024-04-16 · 2y expired

What this patent protects

本披露提供了用于制备如本文描述的化合物A、化合物E、化合物I、其盐、和/或其立体异构体的方法。

USPTO Abstract

本披露提供了用于制备如本文描述的化合物A、化合物E、化合物I、其盐、和/或其立体异构体的方法。

Drugs covered by this patent

vibegron (VIBEGRON)

Patent Metadata

Patent number: CN117897379A
Jurisdiction: CN
Classification: —
Expires: 2024-04-16
Drug substance claim: No
Drug product claim: No
Assignee: Amgen Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.